ARK Investment Boosts Stake in Beam Therapeutics

Firm increases position in gene-editing biotech company by nearly 25%

Published on Mar. 5, 2026

Got story updates? Submit your updates here. ›

ARK Investment Management LLC has increased its stake in Beam Therapeutics Inc. (NASDAQ:BEAM) by 24.8% in the third quarter, according to a recent SEC filing. The investment firm now owns 11,038,834 shares of the gene-editing biotech company, making it Beam's largest institutional shareholder with a 10.88% stake.

Why it matters

Beam Therapeutics is a leading player in the fast-growing field of gene editing, which holds promise for treating a wide range of genetic diseases. ARK's increased investment signals the firm's confidence in Beam's technology and growth potential.

The details

According to the filing, ARK Investment purchased an additional 2,190,993 shares of Beam Therapeutics during the third quarter, bringing its total position to 11,038,834 shares. This makes ARK the largest institutional investor in the company, owning 10.88% of Beam's outstanding shares.

  • ARK Investment increased its Beam Therapeutics stake in the third quarter of 2026.

The players

ARK Investment Management LLC

A prominent investment management firm focused on disruptive innovation, including companies in the genomics and biotechnology sectors.

Beam Therapeutics Inc.

A biotechnology company dedicated to developing precision genetic medicines through its pioneering base editing platform.

Got photos? Submit your photos here. ›

The takeaway

ARK's increased stake in Beam Therapeutics underscores the firm's confidence in the company's gene-editing technology and growth potential. As a leader in the fast-evolving field of precision genetic medicine, Beam's future performance will be closely watched by investors.